- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.11. | Day One Biopharma Expands Oncology Pipeline With $285 Million Mersana Buyout | 5 | Benzinga.com | ||
| 13.11. | Mersana Catapults 200% On Day One Bio's Surprise Buyout | 9 | Investor's Business Daily | ||
| 13.11. | Mersana Therapeutics To Be Acquired By Day One Biopharmaceuticals For Up To $285 Mln | 12 | RTTNews | ||
| 13.11. | Day One Biopharmaceuticals to buy Mersana Therapeutics for $25/share upfront | 3 | Seeking Alpha | ||
| 13.11. | Day One Biopharmaceuticals to acquire Mersana Therapeutics in deal worth up to $285 million | 13 | Investing.com | ||
| 13.11. | Day One Biopharmaceuticals, Inc.: Day One to Acquire Mersana Therapeutics to Advance Mission to Bring New Medicines to People of All Ages with Life-Threatening Diseases | 297 | GlobeNewswire (Europe) | Acquisition expands Day One's portfolio with novel antibody-drug conjugate (ADC) emiltatug ledadotin (Emi-Le) Emi-Le has demonstrated early anti-tumor activity in an ongoing Phase 1 study for adenoid... ► Artikel lesen | |
| DAY ONE BIOPHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 13.11. | Day One Biopharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 05.11. | Day One Biopharmaceuticals raises 2025 revenue guidance to $145M-$150M as OJEMDA sees sustained double-digit growth | 4 | Seeking Alpha | ||
| 05.11. | Day One Biopharmaceuticals Q3 2025 slides: OJEMDA drives 15% revenue growth, guidance raised | 8 | Investing.com | ||
| 04.11. | Day One Biopharmaceuticals, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 04.11. | Day One Biopharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.10. | Day One Biopharmaceuticals, Inc.: Day One to Report Third Quarter 2025 Financial Results Tuesday, November 4, 2025 | 15 | GlobeNewswire (USA) | ||
| 10.10. | Day One Biopharmaceuticals, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 06.08. | Day One Biopharmaceuticals outlines $140M-$150M 2025 OJEMDA revenue target as new patient scripts accelerate | 8 | Seeking Alpha | ||
| 05.08. | Day One Biopharmaceuticals: Umsatzwachstum bei OJEMDA hält an, während die Entwicklungspipeline voranschreitet | 19 | Investing.com Deutsch | ||
| 05.08. | Day One Biopharmaceuticals Non-GAAP EPS of -$0.29 beats by $0.05, revenue of $33.91M misses by $0.99M | 16 | Seeking Alpha | ||
| 05.08. | Day One Biopharmaceuticals, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 05.08. | Day One Biopharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.07. | Day One Biopharmaceuticals, Inc.: Day One to Report Second Quarter 2025 Financial Results Tuesday, August 5, 2025 | 3 | GlobeNewswire (USA) | ||
| 23.06. | TimesSquare Capital U.S. Small Cap Growth Strategy Exited its Position in Day One Biopharmaceuticals Inc. (DAWN) | 7 | Insider Monkey |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 83,05 | +0,06 % | Raus aus BioNTech? Rein in Evotec und Vidac Aktie? Was läuft da mit Johnson und Johnson? | Paukenschläge bei Biotechs: Partner Pfizer verkauft seine komplette Beteiligung am deutschen Biotech-Champion BioNTech. Sollten Anleger es genauso machen? Dagegen liefert Vidac Pharma mehr und mehr... ► Artikel lesen | |
| CUREVAC | 4,346 | -0,59 % | HV-Termine: Hauptversammlungen bei artnet, BVB, Cherry, CureVac, Schloss Wachenheim, SDM, The Grounds | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen | |
| AMGEN | 297,10 | +1,38 % | Dividendenbekanntmachungen (21.11.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACCO BRANDS CORPORATION US00081T1088 0,075 USD 0,065 EUR ALLISON TRANSMISSION HOLDINGS INC US01973R1014 0,27 USD 0,2341 EUR ALPHAMIN... ► Artikel lesen | |
| NOVAVAX | 5,629 | +0,27 % | NOVAVAX INC zittert - jetzt entscheidet sich alles! | ||
| BIOGEN | 152,15 | -0,07 % | Biogen Inc.: Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments | - Despite treatment with standard-of-care anti-seizure medicines, children with Dravet syndrome experienced high seizure burden and plateaued in neurodevelopment, resulting in a widening gap relative... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 44,200 | +1,38 % | Crispr Therapeutics gains amid takeover speculation | ||
| MAINZ BIOMED | 0,986 | -6,94 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed und OncoVanguard8 unterzeichnen Vereinbarung zur Einführung von ColoAlert in Südamerika | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Sonstiges
Mainz Biomed und OncoVanguard8 unterzeichnen Vereinbarung zur Einführung von ColoAlert in Südamerika
18.11.2025... ► Artikel lesen | |
| VIKING THERAPEUTICS | 29,745 | +0,03 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735 | 78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity
Enrollment Completed Ahead of Schedule and Above Target Size, Indicating Strong Interest in... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 7,220 | +1,21 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy | One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-upConsistent trend in disease stability or improvement in multiple measures... ► Artikel lesen | |
| TEMPUS AI | 61,00 | 0,00 % | How Did Tempus AI Power Its Move to Positive EBITDA in Q3? | ||
| BIOCRYST PHARMACEUTICALS | 6,130 | +1,36 % | BIOCRYST PHARMACEUTICALS INC - S-4, Registration of securities, business combinations | ||
| SAREPTA THERAPEUTICS | 15,200 | -1,01 % | FDA Restricts Use of Sarepta's Gene Therapy, Adds Safety Warnings | ||
| BIOMARIN PHARMACEUTICAL | 46,520 | -2,00 % | BioMarin Pharmaceutical Inc.: FDA Accepts BioMarin's PALYNZIQ (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria | Application based on positive results from Phase 3 PEGASUS study, which demonstrated statistically significant blood phenylalanine (Phe) lowering compared to diet... ► Artikel lesen | |
| EXELIXIS | 36,490 | -1,16 % | Wolfe Research initiates Exelixis stock with Peerperform rating | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,900 | -1,66 % | Pacific Biosciences: Mit Long-Read-Sequenzierung zum Angriff auf Illumina |
DAY ONE BIOPHARMACEUTICALS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +2,65 % bei einem Aktienkurs von 8,510 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DAY ONE BIOPHARMACEUTICALS INC finden Sie auf Wallstreet Online.